205 related articles for article (PubMed ID: 31660823)
1. Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant.
Lin CH; Chen YM; Lane HY
Curr Drug Targets; 2020; 21(6):610-615. PubMed ID: 31660823
[TBL] [Abstract][Full Text] [Related]
2. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial.
Lin CH; Lin CH; Chang YC; Huang YJ; Chen PW; Yang HT; Lane HY
Biol Psychiatry; 2018 Sep; 84(6):422-432. PubMed ID: 29397899
[TBL] [Abstract][Full Text] [Related]
3. Sodium benzoate: A novel multi-target pharmaceutical approach to rescue clozapine-resistant schizophrenia.
Lin CH; Lane HY
Schizophr Res; 2024 Jun; 268():261-264. PubMed ID: 37230913
[No Abstract] [Full Text] [Related]
4. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
Shim SS; Hammonds MD; Kee BS
Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
[TBL] [Abstract][Full Text] [Related]
6. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
[TBL] [Abstract][Full Text] [Related]
7. Lack of Effect of Sodium Benzoate at Reported Clinical Therapeutic Concentration on d-Alanine Metabolism in Dogs.
Popiolek M; Tierney B; Steyn SJ; DeVivo M
ACS Chem Neurosci; 2018 Nov; 9(11):2832-2837. PubMed ID: 29893546
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
Singh SP; Singh V
CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
Lin CY; Liang SY; Chang YC; Ting SY; Kao CL; Wu YH; Tsai GE; Lane HY
World J Biol Psychiatry; 2017 Aug; 18(5):357-368. PubMed ID: 26691576
[TBL] [Abstract][Full Text] [Related]
10. D-serine added to clozapine for the treatment of schizophrenia.
Tsai GE; Yang P; Chung LC; Tsai IC; Tsai CW; Coyle JT
Am J Psychiatry; 1999 Nov; 156(11):1822-5. PubMed ID: 10553752
[TBL] [Abstract][Full Text] [Related]
11. Augmentation Strategies for Clozapine-Resistant Patients with Schizophrenia.
Chiu YH; Hsu CY; Lu ML; Chen CH
Curr Pharm Des; 2020; 26(2):218-227. PubMed ID: 31924152
[TBL] [Abstract][Full Text] [Related]
12. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
Tsai GE; Lin PY
Curr Pharm Des; 2010; 16(5):522-37. PubMed ID: 19909229
[TBL] [Abstract][Full Text] [Related]
13. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
Veerman SR; Schulte PF; Smith JD; de Haan L
Psychol Med; 2016 Jul; 46(9):1909-21. PubMed ID: 27048954
[TBL] [Abstract][Full Text] [Related]
14. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.
Lin CH; Chen PK; Chang YC; Chuo LJ; Chen YS; Tsai GE; Lane HY
Biol Psychiatry; 2014 May; 75(9):678-85. PubMed ID: 24074637
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of
Goh KK; Wu TH; Chen CH; Lu ML
J Psychopharmacol; 2021 Mar; 35(3):236-252. PubMed ID: 33406959
[TBL] [Abstract][Full Text] [Related]
16. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
[TBL] [Abstract][Full Text] [Related]
17. Targeting of NMDA receptors in new treatments for schizophrenia.
Hashimoto K
Expert Opin Ther Targets; 2014 Sep; 18(9):1049-63. PubMed ID: 24965576
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia.
Ferraris DV; Tsukamoto T
Curr Pharm Des; 2011; 17(2):103-11. PubMed ID: 21361869
[TBL] [Abstract][Full Text] [Related]
19. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
Javitt DC
Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
[TBL] [Abstract][Full Text] [Related]
20. Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.
Sershen H; Hashim A; Dunlop DS; Suckow RF; Cooper TB; Javitt DC
Neurochem Res; 2016 Feb; 41(1-2):398-408. PubMed ID: 26857796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
